TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8647327

Group type: EXPERIMENTAL
Intervention: Developmental language disorder (phonologic‐syntactic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Developmental language disorder (semantic‐pragmatic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-level autism
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (normal children)
Number of subjects: 0
Study: 1906160

Group type: EXPERIMENTAL
Intervention: Cefprozil (30 mg/kg/day divided into two equal doses)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Amoxicillin clavulanate potassium (40 mg/kg/day divided into three equal doses)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Cefprozil
Number of subjects: 137

Group type: COMPARATOR
Intervention: Amoxicillin clavulanate potassium
Number of subjects: 137
Study: 6137601

Group type: EXPERIMENTAL
Intervention: Aldose reductase inhibitor ('Sorbinil'‐‐Pfizer CP 45, 634)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 29458919

Group type: EXPERIMENTAL
Intervention: Yoga meditation (YoMed)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Proprioceptive Training (PT)
Number of subjects: 16
Study: 26782847

Group type: EXPERIMENTAL
Intervention: Hybrid devices
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tooth-borne (TB) devices (Hyrax)
Number of subjects: 20
Study: 23890072

Group type: EXPERIMENTAL
Intervention: Simplified method (group S)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional method (group C)
Number of subjects: 39
Study: 23052819

Group type: EXPERIMENTAL
Intervention: Ponseti method for idiopathic clubfeet
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Ponseti method for non-idiopathic clubfeet
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Abduction splint treatment compliance
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Relapse surgery
Number of subjects: 101
Study: 20349354

Group type: EXPERIMENTAL
Intervention: High-impact exercise (HIE) for 12 months
Number of subjects: 91

Group type: COMPARATOR
Intervention: Stretching exercise (SE) for 12 months
Number of subjects: 91
Study: 18656044

Group type: EXPERIMENTAL
Intervention: Injury prevention program
Number of subjects: 262
Study: 15816472

Group type: EXPERIMENTAL
Intervention: Antioxidant biofactor AOB (3x2 sachets of 3 g powder each for 3 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (herbal extract with no superoxide scavenging properties)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Conventional antiviral treatment (pegylated interferon alpha and ribavirin) after 3 months
Number of subjects: 30
Study: 12818407

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 122
Study: 11328968

Group type: EXPERIMENTAL
Intervention: Natural surfactant
Number of subjects: 21

Group type: COMPARATOR
Intervention: Synthetic surfactant
Number of subjects: 21
Study: 8692168

Group type: EXPERIMENTAL
Intervention: Meta-analysis of randomized control trials
Number of subjects: 164
Study: 1644539

Group type: EXPERIMENTAL
Intervention: Surgical drainage
Number of subjects: 97

Group type: COMPARATOR
Intervention: No surgical drainage
Number of subjects: 97
Study: 6369669

Group type: EXPERIMENTAL
Intervention: High-dose steroids with azathioprine
Number of subjects: 189

Group type: COMPARATOR
Intervention: Low-dose steroids with azathioprine
Number of subjects: 189
Study: 29943058

Group type: EXPERIMENTAL
Intervention: One-Anastomosis Gastric Bypass (OAGB)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 600
Study: 31234808

Group type: EXPERIMENTAL
Intervention: Conventional disinfection group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-disinfection group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cesarean section group
Number of subjects: 20
Study: 25367165

Group type: EXPERIMENTAL
Intervention: Gradual switch to iloperidone (n=240)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Immediate switch to iloperidone (n=260)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Both groups (Gradual and Immediate switch)
Number of subjects: 500
Study: 23365418

Group type: EXPERIMENTAL
Intervention: Regular moderate-intensity exercise (three training sessions/week, 50-55 min/session)
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Regular moderate-intensity exercise
Number of subjects: 510

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 510
Study: 22056450

Group type: EXPERIMENTAL
Intervention: 0.6% energy trans fatty acid (TFA) intake
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no TFA intake)
Number of subjects: 0
Study: 19231581

Group type: EXPERIMENTAL
Intervention: HIFU ablation of the primary breast cancer prior to modified radical mastectomy (n = 23)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group with modified radical mastectomy only (n = 25)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: HIFU group (n = 23)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (n = 25)
Number of subjects: 48
Study: 16536341

Group type: EXPERIMENTAL
Intervention: Adper Prompt L‐Pop (APLP)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Prompt L‐Pop 2 (PLP)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Scotchbond Multipurpose Plus (SMP)
Number of subjects: 120
Study: 12626303

Group type: EXPERIMENTAL
Intervention: Fast track protocol (group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional anesthesia (group B)
Number of subjects: 100
Study: 11011808

Group type: EXPERIMENTAL
Intervention: tinzaparin
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: enoxaparin
Number of subjects: 499
Study: 9295822

Group type: EXPERIMENTAL
Intervention: Immunonutritional diet (n = 77)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Isocaloric and isonitrogenous placebo diet (n = 77)
Number of subjects: 154
Study: 7801580

Group type: EXPERIMENTAL
Intervention: CA125 measurements
Number of subjects: 131

Group type: COMPARATOR
Intervention: CEA measurements
Number of subjects: 131
Study: 3521518

Group type: EXPERIMENTAL
Intervention: Oral bacitracin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oral vancomycin
Number of subjects: 24
Study: 28395549

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 1944

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1944
Study: 26379068

Group type: EXPERIMENTAL
Intervention: HIV-1 Gag- and Nef-transfected DCs (vaccine)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Mock-transfected DCs (placebo)
Number of subjects: 15
Study: 25486673

Group type: EXPERIMENTAL
Intervention: Web-based physical activity program (Philips DirectLife) for 12 weeks
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Increase in minutes spent in moderate-to-vigorous activity
Number of subjects: 235
Study: 22936148

Group type: EXPERIMENTAL
Intervention: Caloric test with air at 50ºC
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Caloric test with air at 24ºC
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Caloric test with water at 44ºC
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Caloric test with water at 30ºC
Number of subjects: 40
Study: 21275332

Group type: EXPERIMENTAL
Intervention: Music therapy (MT) sessions multiple times per week
Number of subjects: 61
Study: 18162944

Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine
Number of subjects: 0
Study: 16168533

Group type: EXPERIMENTAL
Intervention: Unexpected fast impact (10.0m/s2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Unexpected slow impact (4.5m/s2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All impacts
Number of subjects: 30
Study: 12941198

Group type: EXPERIMENTAL
Intervention: Recent advances in biologic response modifier therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy
Number of subjects: 0
Study: 10230954

Group type: EXPERIMENTAL
Intervention: Amrinone (loading dose of 2 mg/kg, maintenance infusion of 7.5 microg/kg/min)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Amrinone
Number of subjects: 35

Group type: COMPARATOR
Intervention: Dopamine and nitroglycerin (dopamine 5 microg/kg/min, nitroglycerin 1 microg/kg/min)
Number of subjects: 35
Study: 8674002

Group type: EXPERIMENTAL
Intervention: Second-line hormonal therapy with megestrol acetate or fadrozole
Number of subjects: 300
Study: 1688356

Group type: EXPERIMENTAL
Intervention: Ambroxol (1 g/day intravenously for 6 consecutive days)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 7017343

Group type: EXPERIMENTAL
Intervention: Insulin infusion at a rate of 0.33 mU/kg/min
Number of subjects: 5

Group type: COMPARATOR
Intervention: No insulin infusion (control)
Number of subjects: 5
Study: 31553457

Group type: EXPERIMENTAL
Intervention: NKTR-181 400 mg
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: NKTR-181 600 mg
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: NKTR-181 400 mg and 600 mg
Number of subjects: 71

Group type: COMPARATOR
Intervention: Oxycodone 40 mg
Number of subjects: 71

Group type: COMPARATOR
Intervention: Oxycodone 60 mg
Number of subjects: 71

Group type: COMPARATOR
Intervention: Oxycodone
Number of subjects: 71
Study: 30813155

Group type: EXPERIMENTAL
Intervention: Trigger point dry needling
Number of subjects: 160

Group type: COMPARATOR
Intervention: Sham dry needling
Number of subjects: 160
Study: 29265090

Group type: EXPERIMENTAL
Intervention: Tolpersione injection and oral formulations combined with NSAID
Number of subjects: 239

Group type: COMPARATOR
Intervention: NSAID monotherapy
Number of subjects: 239
Study: 25453481

Group type: EXPERIMENTAL
Intervention: High dose exercise regimen
Number of subjects: 39

Group type: COMPARATOR
Intervention: Low dose exercise regimen
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both exercise groups
Number of subjects: 39
Study: 24428754

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg daily for 7 days
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg daily for 7 days
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both clopidogrel and prasugrel
Number of subjects: 54
Study: 18637782

Group type: EXPERIMENTAL
Intervention: 100 mg of enteric-coated aspirin tablets daily
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 15060224

Group type: EXPERIMENTAL
Intervention: Medication management (MedMgt)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Combination therapy (Comb)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Behavior modification therapy (Beh)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Usual community comparison (CC)
Number of subjects: 540
Study: 11753057

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection with rehabilitation
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sham injection with rehabilitation
Number of subjects: 39
Study: 8997805

Group type: EXPERIMENTAL
Intervention: Biofeedback-relaxation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 8480506

Group type: EXPERIMENTAL
Intervention: Isradipine (0.0010, 0.0020, 0.0040, 0.0080 mg.kg‐1; total 0.0150 mg.kg‐1)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Verapamil (0.0125, 0.0250, 0.0500, 0.1000 mg.kg‐1; total 0.1875 mg.kg‐1)
Number of subjects: 19
Study: 3321926

Group type: EXPERIMENTAL
Intervention: 1 microgram alphacalcidol
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 11376175

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (200 units, 40 units/site at five lumbar paravertebral levels)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 31
Study: 31300167

Group type: EXPERIMENTAL
Intervention: Vibration
Number of subjects: 0
Study: 30052211

Group type: EXPERIMENTAL
Intervention: Intraoperative transesophageal echocardiography (TEE)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 80
Study: 26885528

Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP) plus B Complex (B1/B12)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Pregabalin (PGB)
Number of subjects: 270
Study: 24310050

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N₂O) anesthesia
Number of subjects: 442

Group type: COMPARATOR
Intervention: No nitrous oxide (N₂O) anesthesia
Number of subjects: 442
Study: 22367114

Group type: EXPERIMENTAL
Intervention: Rebamipide (15 mg, t.i.d. for 4 weeks)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo (t.i.d. for 4 weeks)
Number of subjects: 146
Study: 20162245

Group type: EXPERIMENTAL
Intervention: Low dose dobutamine infusion
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 89
Study: 17192164

Group type: EXPERIMENTAL
Intervention: Ramelteon (melatonin receptor agonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benzodiazepine and nonbenzodiazepine sedative-hypnotic agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sedating antihistamines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Melatonin (herbal preparation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valerian (herbal preparation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (nonpharmacologic option)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relaxation therapy (nonpharmacologic option)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sleep hygiene education (nonpharmacologic option)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sleep restriction (nonpharmacologic option)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paradoxical intention (nonpharmacologic option)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biofeedback (nonpharmacologic option)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulus control (nonpharmacologic option)
Number of subjects: 0
Study: 15589562

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 329

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329
Study: 12404219

Group type: EXPERIMENTAL
Intervention: Aspirin (500 mg 3 times daily) for 5 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo for 5 days
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Aspirin (5 days)
Number of subjects: 28
Study: 10622992

Group type: EXPERIMENTAL
Intervention: Enhanced emergency department referral to primary care
Number of subjects: 189

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 189
Study: 7772423

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 73

Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Neonatal outcomes
Number of subjects: 73
Study: 2186494

Group type: EXPERIMENTAL
Intervention: alpha 2‐interferon (alpha 2‐IF)
Number of subjects: 412
Study: 286280

Group type: EXPERIMENTAL
Intervention: Inclined footrest
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional panoramic technique without inclined footrest
Number of subjects: 0
Study: 31629373

Group type: EXPERIMENTAL
Intervention: Active thermography + standard foot care
Number of subjects: 110

Group type: COMPARATOR
Intervention: Blinded thermography + standard foot care
Number of subjects: 110
Study: 31499384

Group type: EXPERIMENTAL
Intervention: Active supportive care (ASC) + oral erlotinib
Number of subjects: 527

Group type: COMPARATOR
Intervention: Active supportive care (ASC) only
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: ECOG 0-1
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: ECOG 2-3
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Age ≥ 75 years
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Stage IV
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 527
Study: 27854142

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC+)
Number of subjects: 69

Group type: COMPARATOR
Intervention: No Mitomycin C (MMC‐)
Number of subjects: 69
Study: 25913109

Group type: EXPERIMENTAL
Intervention: Δ(9)-THC at .015 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Δ(9)-THC at .03 mg/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Δ(9)-THC (both doses)
Number of subjects: 24
Study: 23329342

Group type: EXPERIMENTAL
Intervention: Acoustic stimulation
Number of subjects: 104

Group type: COMPARATOR
Intervention: Feeding mother stimulation
Number of subjects: 104
Study: 20610478

Group type: EXPERIMENTAL
Intervention: RPE‐choroid sheet transplantation (group 1)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: RPE cell‐suspension transplantation (group 2)
Number of subjects: 14
Study: 19283647

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Other anticonvulsants
Number of subjects: 12
Study: 17760538

Group type: EXPERIMENTAL
Intervention: SCRF‐E group (semilunar coronally repositioned flap with EDTA application)
Number of subjects: 15

Group type: COMPARATOR
Intervention: SCRF group (semilunar coronally repositioned flap without EDTA application)
Number of subjects: 15
Study: 15061348

Group type: EXPERIMENTAL
Intervention: Prolonged exposure with cognitive restructuring
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Prolonged exposure without cognitive restructuring
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Community therapists
Number of subjects: 75

Group type: COMPARATOR
Intervention: Cognitive behavioral treatment experts
Number of subjects: 75
Study: 11210393

Group type: EXPERIMENTAL
Intervention: Eniporide (2.5 to 100 mg, administered intravenously)
Number of subjects: 0
Study: 9744152

Group type: EXPERIMENTAL
Intervention: 50 mg mibefradil
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: 100 mg mibefradil
Number of subjects: 618

Group type: COMPARATOR
Intervention: mibefradil
Number of subjects: 618
Study: 7800183

Group type: EXPERIMENTAL
Intervention: Ventilatory setting with constant tidal volume (VC = 8 ml.kg‐1) and varying respiratory frequencies (f = 10, 12, and 14 breaths.min‐1)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Constant ventilation (112 ml.kg‐1) with modified VC and f
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Inspiratory volume set to achieve an end-tidal PCO2 (PETCO2) of about 35 mmHg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: General surgery (not directly relevant to the measures)
Number of subjects: 28
Study: 3288029

Group type: EXPERIMENTAL
Intervention: gemfibrozil alone
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: gemfibrozil and colestipol
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: gemfibrozil and lovastatin
Number of subjects: 17
Study: 29315699

Group type: EXPERIMENTAL
Intervention: Regorafenib eye drops (30 mg ml-1, 25 μl) as a 0.75 mg single dose (Cohort 1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Regorafenib eye drops (0.75 mg twice daily for 14 days, Cohort 2)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Regorafenib eye drops (0.75 mg thrice daily for 14 days, Cohort 3)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Regorafenib eye drops (1.5 mg thrice daily unilaterally for 3 days, then bilaterally for up to 14 days, Cohort 4)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Regorafenib eye drops (0.75 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Systemic safety evaluations
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Regorafenib eye drops (up to 30 mg ml-1 tid)
Number of subjects: 48
Study: 28801429

Group type: EXPERIMENTAL
Intervention: H pylori eradication combined with pepsinogen testing
Number of subjects: 30000

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 30000
Study: 26170291

Group type: EXPERIMENTAL
Intervention: Self-control
Number of subjects: 292
Study: 24122883

Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triamcinolone acetonide
Number of subjects: 0
Study: 21392707

Group type: EXPERIMENTAL
Intervention: Radial artery graft
Number of subjects: 0

Group type: COMPARATOR
Intervention: Right internal thoracic artery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saphenous vein graft
Number of subjects: 0
Study: 18049099

Group type: EXPERIMENTAL
Intervention: 370 MBq of 188Re‐labelled nimotuzumab
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 555 MBq of 188Re‐labelled nimotuzumab
Number of subjects: 9
Study: 16773342

Group type: EXPERIMENTAL
Intervention: Alfentanil-propofol (group 4)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Alfentanil-propofol under induction with sevoflurane (group 3)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Sevoflurane-nitrous oxide/oxygen (group 1)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Sevoflurane-air/alfentanil (group 2)
Number of subjects: 103
Study: 12577163

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of tramadol (20 mg/ml) and dipyrone (200 mg/ml)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Patient controlled analgesia (PCA) with tramadol (20 mg/ml) and dipyrone (200 mg/ml)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of tramadol and dipyrone
Number of subjects: 191

Group type: COMPARATOR
Intervention: Patient controlled analgesia (PCA) with tramadol and dipyrone
Number of subjects: 191
Study: 10858338

Group type: EXPERIMENTAL
Intervention: Nelfinavir at a dose of 500 or 750 mg three times a day
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Nelfinavir with concomitant fluconazole therapy
Number of subjects: 174

Group type: COMPARATOR
Intervention: Nelfinavir without fluconazole therapy
Number of subjects: 174
Study: 9337501

Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Usual juvenile justice services
Number of subjects: 155
Study: 1279570

Group type: EXPERIMENTAL
Intervention: DDDR pacing
Number of subjects: 8
Study: 4030048

Group type: EXPERIMENTAL
Intervention: Naloxone (opiate antagonist)
Number of subjects: 0
Study: 31512741

Group type: EXPERIMENTAL
Intervention: Body and movement oriented intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0